Second-look laparotomy for stage III epithelial ovarian cancer: rationale and current issues

Cancer Treatment Reviews

Volumn 21, Issue 6, 1995, Pages 499-511

  Muderspach, Laila ^a   Muggia, Franco M ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; PACLITAXEL; PLATINUM DERIVATIVE;

CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LABORATORY TEST; LAPAROSCOPY; LAPAROTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHYSICAL EXAMINATION; PROGNOSIS; REVIEW; TREATMENT OUTCOME; ULTRASOUND;

EPITHELIUM; FEMALE; HUMANS; LAPAROTOMY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; REOPERATION;

EID: 0029555056     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/0305-7372(95)90014-4     Document Type: Article

References (60)

1. Management of ovarian cancer
2. Staging announcement
3. Cancer of the ovary
4. A phase III trial comparing cisplatinl Cytoxan and cisplatin/Taxol in advanced ovarian cancer
5. Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission: correlation with surgical-pathologic findings
6. The CA-125 assay as a predictor of clinical recurrence in epithelial ovarian cancer
7. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer
8. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer
9. A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma
10. Second-look laparotomy and salvage therapy: a research modality only?
11. A predictive index of cure versus no cure in advanced ovarian carcinoma patients-replacement of second-look laparotomy as a diagnostic test
12. Second thought about second-look laparotomy in advanced ovarian cancer
13. Second-look versus second-nature
14. Uselessness of surgical second-look in epithelial ovarian cancer: a randomized study
15. Tumors of the ovary
16. Second-look laparotomy and prognosis related to extent of residual disease
17. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)-the Mount Sinai Experience
18. Prognosis of surgically determined complete responders in advanced ovarian cancer
19. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma
20. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens
21. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy
22. Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography
23. Intraperitoneal carboplatin: favourable response in women with minimal residual ovarian cancer after cisplatin therapy
24. The influence of initial residual disease on the outcome of second-look laparotomy in patients with carcinoma of the ovary
25. Second-look laparotomy after chemotherapy in the management of ovarian malignancy
26. A review of second-look laparotomy for ovarian cancer
27. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma
28. A reassessment of the role of second-look laparotomy in advanced ovarian cancer
29. Evaluation of the role of second-look surgery in ovarian cancer
30. Long-term survival in ovarian cancer
31. A formula for predicting the risk of a positive second-look laparotomy in epithelial ovarian cancer: implications for a randomized trial
32. Que restet-il de la laparotomie de deuxième vue dans le traitement des cancers de l'ovaire?
33. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma
34. Second-look laparotomy in ovarian cancer: evaluation of pathologic variables
35. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status
36. Second-look laparotomy in Stage I ovarian cancer following comprehensive surgical staging
37. Secondary cytoreduction-thoughts on the “pro” side
38. Secondary cytoreduction in ovarian cancer: pro or con?
39. The effect of debulking after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
40. Surgery in the treatment of patients with advanced ovarian cancer
41. A comparison of findings at second-look laparotomy with preoperative computed tomography in patients with ovarian cancer
42. Accuracy of CT in detection of persistent or recurrent ovarian carcinoma: correlation with second-look laparotomy
43. Correlation of abdominal ultrasound and computed tomography scans with second- or third-look laparotomy in patients with ovarian carcinoma
44. Correlation of abdominal computed tomography scanning and second-look operation findings in ovarian cancer patients
45. Use of the computed tomographic whole body scanner to stage and follow patients with advanced ovarian carcinoma
46. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma
47. Predictive value of CA125 antigen levels in second-look procedures for ovarian cancer
48. CA 125 levels correlated with second-look operations among ovarian cancer patients
49. CA 125 serum levels and secondary laparotomy in epithelial ovarian tumors
50. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer
51. Monoclonal antibodies in ovarian and prostate cancer
52. FDG PET imaging of ovarian cancer: initial evaluation in patients
53. FDGPET imaging for post treatment evaluation of patients with genitourinary (GU) malignancies
54. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using F-[18]-deoxyglucose (2-[18F]FDG)
55. Assessment of primary and recurrent cancer of the ovary using F-18-FDG PET
56. Detection of residual/recurrent ovarian cancer using PET-FDG imaging
57. Experience with positron emission tomography (PET) scans in patients with ovarian cancer
58. Whole-body positron emission tomography with 2-[F-18]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma
59. Whole body positron emission tomography with (F-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube
60. Ovarian cancer: monitoring by paracentesis wash